This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Milas, L. Articles by Hunter, N. Search for Related Content PubMed PubMed Citation Articles by Milas, L. Articles by Hunter, N.

Effect of Tumor Size on S-2-(3-Aminopropylamino)ethylphosphorothioic Acid and Misonidazole Alteration of Tumor Response to Cyclophosphamide¹

Department of Experimental Radiotherapy, The University of Texas, M. D. Anderson Hospital and Tumor Institute at Houston, Houston, Texas 77030

The influence of tumor size on the ability of S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR-2721) or misonidazole (MISO) to alter cyclophosphamide (CY) antitumor activity was investigated, using a chemically induced fibrosarcoma (FSA) and a spontaneous fibrosarcoma (NFSA) in C3Hf/Kam mice. Tumors were of two sizes at the time of treatment, 8-mm leg tumors and 4-day-old micrometastases in the lung. The antitumor activity of CY and its modification were assessed by growth delay of leg tumors and the reduction in the number of lung metastases. Both measures of tumor response were more pronounced as the dose of CY increased, and FSA was more sensitive to CY than was NFSA. WR-2721 (400 mg/kg), given 30 min before treatment with CY, reduced the effectiveness of CY on both FSA and NFSA. This reduction in effectiveness of CY was only minimal for leg tumors (dose-modifying factors were 1.1 for FSA and 1.03 for NFSA) but remarkable for lung micrometastases (dose-modifying factors were 1.81 for FSA and 1.55 for NFSA). Protection increased with the increase in the dose of WR-2721 and was also dependent on the time of injection relative to CY. The greatest protection occurred when WR-2721 was given within 30 min before to 15 min after CY. Tumor size had the opposite effect on MISO from that on WR-2721. MISO (1 mg/g) enhanced the effect of CY more effectively for leg tumors than for lung micrometastases: dose-modifying factors were 1.74 for FSA and 2.21 for NFSA growing in the leg and 1.27 for FSA and 1.11 for NFSA lung micrometastases. Therefore, tumor size appears to be a very important factor in determining the extent of WR-2721- and MISO-induced modification of CY antitumor effect.

¹ This investigation was supported in part by NIH Grant CA-06294 and the author's institutional funds, Account 175439. Animals used in this study were maintained in facilities approved by the American Association for Accreditation of Laboratory Animal Care and in accordance with current regulations and standards of the United States Department of Health and Human Services, NIH.

² To whom requests for reprints should be addressed.

³ On leave of absence from Department of Radiology, Keio University, School of Medicine, Tokyo, Japan.

Received 8/19/82. Accepted 3/28/83.

This article has been cited by other articles:

				M. Summerhayes Review : Amifostine and other chemoprotective agents in cancer chemotherapy: A brief review Journal of Oncology Pharmacy Practice, December 1, 1995; 1(4): 21 - 31. [Abstract] [PDF]